Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

361
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
361
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

684
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
684
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

251
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
251
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

30
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
Neural Regulation01:37

Neural Regulation

39.7K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.7K
Cancer Prevention02:59

Cancer Prevention

6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.3K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Early Alzheimer´s disease blood biomarkers are associated with a higher risk for postoperative long-term cognitive decline: Insights from the FINDERI study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

A comprehensive assessment of lifecourse and mortality of Parkinson's disease in the German National Cohort.

NPJ Parkinson's disease·2026
Same author

Teleguided Point-of-Care Ultrasound for Fluid Assessment in Geriatric Inpatients Performed by Nurses and Medical Students: Prospective Observational Feasibility Study.

JMIR formative research·2026
Same author

Genetic associations between post-traumatic stress disorder and REM-sleep behavior disorder.

NPJ Parkinson's disease·2026
Same author

A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism.

Nature medicine·2026
Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026

Video Experimental Relacionado

Updated: Sep 1, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

Para la prevención de la enfermedad de Parkinson

Brit Mollenhauer1, Christine A F von Arnim2

  • 1Department of Neurology, University Medical Center Göttingen and Paracelsus-Elena-Klinik, Kassel, Germany.

Science (New York, N.Y.)
|August 18, 2022
PubMed
Resumen

Una glicoproteína específica puede servir como un indicador temprano de la progresión de la enfermedad de Parkinson. Este hallazgo podría conducir a un mejor seguimiento de la condición neurodegenerativa.

Más Videos Relacionados

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.9K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.1K

Videos de Experimentos Relacionados

Last Updated: Sep 1, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K
Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

2.9K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.1K

Área de la Ciencia:

  • Neurobiología
  • Descubrimiento de biomarcadores

Sus antecedentes:

  • La enfermedad de Parkinson es un trastorno neurodegenerativo progresivo.
  • La identificación de biomarcadores fiables para la progresión de la enfermedad es crucial para una gestión eficaz.

Objetivo del estudio:

  • Investigar el potencial de una glicoproteína específica como biomarcador para la progresión patógena de la enfermedad de Parkinson.

Principales métodos:

  • Análisis de los niveles de glicoproteína en las muestras biológicas pertinentes.
  • Correlación de los niveles de glicoproteína con la gravedad de la enfermedad y los marcadores de progresión.

Principales resultados:

  • Se identificó una glicoproteína en particular como un indicador potencial de la progresión de la enfermedad de Parkinson.

Conclusiones:

  • Esta glicoproteína es prometedora como biomarcador para el control de la enfermedad de Parkinson.
  • Se necesita más investigación para validar su utilidad clínica.